Aura Biosciences Inc
NASDAQ:AURA
Intrinsic Value
Aura Biosciences, Inc. is a clinical-stage oncology company. [ Read More ]
The intrinsic value of one AURA stock under the Base Case scenario is 4.58 USD. Compared to the current market price of 7.06 USD, Aura Biosciences Inc is Overvalued by 35%.
Valuation Backtest
Aura Biosciences Inc
Run backtest to discover the historical profit from buying and selling AURA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Aura Biosciences Inc
Current Assets | 231.8m |
Cash & Short-Term Investments | 226.2m |
Other Current Assets | 5.6m |
Non-Current Assets | 23.3m |
PP&E | 22m |
Other Non-Current Assets | 1.3m |
Current Liabilities | 12.4m |
Accounts Payable | 1.8m |
Accrued Liabilities | 9.6m |
Other Current Liabilities | 935k |
Non-Current Liabilities | 16.9m |
Other Non-Current Liabilities | 16.9m |
Earnings Waterfall
Aura Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-85m
USD
|
Operating Income
|
-85m
USD
|
Other Expenses
|
8.6m
USD
|
Net Income
|
-76.4m
USD
|
Free Cash Flow Analysis
Aura Biosciences Inc
What is Free Cash Flow?
AURA Profitability Score
Profitability Due Diligence
Aura Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Aura Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
AURA Solvency Score
Solvency Due Diligence
Aura Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Aura Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AURA Price Targets Summary
Aura Biosciences Inc
According to Wall Street analysts, the average 1-year price target for AURA is 20.2 USD with a low forecast of 19.19 USD and a high forecast of 22.05 USD.
Ownership
AURA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AURA Price
Aura Biosciences Inc
Average Annual Return | -8.13% |
Standard Deviation of Annual Returns | 49.62% |
Max Drawdown | -72% |
Market Capitalization | 348.4m USD |
Shares Outstanding | 49 350 800 |
Percentage of Shares Shorted | 6.75% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).
Contact
IPO
Employees
Officers
The intrinsic value of one AURA stock under the Base Case scenario is 4.58 USD.
Compared to the current market price of 7.06 USD, Aura Biosciences Inc is Overvalued by 35%.